Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are two of the most-studied incretin-based research compounds in modern metabolic research. Both target pathways related to glucose regulation and energy metabolism, but they differ significantly in their receptor activity, study outcomes, and pharmacological profiles. This comparison summarizes published research literature to help researchers select the appropriate compound for their study design.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor activity | GLP-1 mono-agonist | GLP-1 + GIP dual agonist |
| Developer | Novo Nordisk | Eli Lilly |
| Half-life (research data) | ~7 days | ~5 days |
| Molecular weight | ~4,114 Da | ~4,813 Da |
| Mechanism complexity | Single pathway | Dual pathway |
About Semaglutide
Semaglutide is a GLP-1 receptor agonist extensively studied since 2012. It binds selectively to the GLP-1 receptor, mimicking the action of the naturally occurring incretin hormone. In research settings, semaglutide has been investigated for its effects on insulin secretion, gastric emptying, and appetite-related pathways in animal models. Its long half-life (~7 days in published pharmacokinetic studies) supports once-weekly dosing protocols in research.
About Tirzepatide
Tirzepatide is a newer compound (first published 2018) that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism is unique among current GLP analogs in research. Published clinical trial data has shown more pronounced effects on metabolic markers compared to GLP-1 mono-agonists in head-to-head studies, though individual response varies. Half-life is approximately 5 days.
Which Should Researchers Choose?
The choice depends on the research question:
- For GLP-1-only mechanism research, semaglutide remains the most well-characterized choice with the largest body of published data.
- For dual-receptor studies exploring GLP-1 + GIP interactions, tirzepatide is the appropriate choice.
- For comparison studies, both compounds are often included to assess single vs. dual agonism.
Both compounds are research peptides intended strictly for laboratory study.
Shop these compounds
Frequently Asked Questions
What is the main difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor mono-agonist (binds one receptor type), while tirzepatide is a dual GLP-1/GIP receptor agonist. This dual mechanism is the key pharmacological distinction in the research literature.
Which has a longer half-life?
Semaglutide has a slightly longer published half-life (~7 days) compared to tirzepatide (~5 days).
Are these research compounds the same as FDA-approved drugs?
Branded pharmaceutical versions of both compounds are FDA-approved for human use. The research-grade versions sold by vendors are NOT approved for human consumption and are intended strictly for laboratory research use only.